XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2020 $ 55,577 $ 104,208,958 $ (70,593,867) $ 33,670,668 $ 33,670,668
Balance (in Shares) at Sep. 30, 2020   55,576,996          
Issuance of NoveCite common stock 1,799,640 (2,399,520) (599,880) 600,380 500
Stock-based compensation expense 276,582 276,582 276,582
Net loss (8,146,909) (8,146,909) (8,146,909)
Balance at Dec. 31, 2020 $ 55,577 106,285,180 (81,140,296) 25,200,461 600,380 25,800,841
Balance (in Shares) at Dec. 31, 2020   55,576,996          
Issuance of common stock in private placement offering, net of costs of $1,549,602 $ 15,456 18,434,954 18,450,410 18,450,410
Issuance of common stock in private placement offering, net of costs of $1,549,602 (in Shares)   15,455,960          
Issuance of common stock in registered direct offering, net of costs of $5,520,160 $ 50,830 70,929,012 70,979,842 70,979,842
Issuance of common stock in registered direct offering, net of costs of $5,520,160 (in Shares)   50,830,566          
Issuance of common stock upon exercise of warrants $ 12,788 14,229,755 14,242,543 14,242,543
Issuance of common stock upon exercise of warrants (in Shares)   12,787,697          
Issuance of common stock for services $ 50 67,950 68,000 68,000
Issuance of common stock for services (in Shares)   50,000          
Stock-based compensation expense 342,962 342,962 342,962
Net loss (4,122,432) (4,122,432) (4,122,432)
Balance at Mar. 31, 2021 $ 134,701 210,289,813 (85,262,728) 125,161,786 600,380 125,762,166
Balance (in Shares) at Mar. 31, 2021   134,701,219          
Balance at Sep. 30, 2021 $ 145,979 228,084,195 (96,047,821) 132,182,353 600,380 132,782,733
Balance (in Shares) at Sep. 30, 2021   145,979,429          
Issuance of common stock for services $ 50 95,834 95,884 95,884
Issuance of common stock for services (in Shares)   50,201          
Stock-based compensation expense 904,604 904,604 904,604
Net loss (9,225,220) (9,225,220) (9,225,220)
Balance at Dec. 31, 2021 $ 146,029 229,084,633 (105,273,041) 123,957,621 600,380 124,558,001
Balance (in Shares) at Dec. 31, 2021   146,029,630          
Issuance of common stock for services $ 100 177,900 178,000 178,000
Issuance of common stock for services (in Shares)   100,000          
Stock-based compensation expense 1,020,998 1,020,998 1,020,998
Net loss (7,561,054) (7,561,054) (7,561,054)
Balance at Mar. 31, 2022 $ 146,129 $ 230,283,531 $ (112,834,095) $ 117,595,565 $ 600,380 $ 118,195,945
Balance (in Shares) at Mar. 31, 2022   146,129,630